keyword
MENU ▼
Read by QxMD icon Read
search

Peritoneal dialysis solutions

keyword
https://www.readbyqxmd.com/read/28708209/changes-of-peritoneal-transport-parameters-with-time-on-dialysis-assessment-with-sequential-peritoneal-equilibration-test
#1
Jacek Waniewski, Stefan Antosiewicz, Daniel Baczynski, Jan Poleszczuk, Mauro Pietribiasi, Bengt Lindholm, Zofia Wankowicz
BACKGROUND: Sequential peritoneal equilibration test (sPET) is based on the consecutive performance of the peritoneal equilibration test (PET, 4-hour, glucose 2.27%) and the mini-PET (1-hour, glucose 3.86%), and the estimation of peritoneal transport parameters with the 2-pore model. It enables the assessment of the functional transport barrier for fluid and small solutes. The objective of this study was to check whether the estimated model parameters can serve as better and earlier indicators of the changes in the peritoneal transport characteristics than directly measured transport indices that depend on several transport processes...
July 11, 2017: International Journal of Artificial Organs
https://www.readbyqxmd.com/read/28698252/peritoneal-equilibration-test-reference-values-using-a-3-86-glucose-solution-during-the-first-year-of-peritoneal-dialysis-results-of-a-multicenter-study-of-a-large-patient-population
#2
Vincenzo La Milia, Gianfranca Cabiddu, Giovanbattista Virga, Valerio Vizzardi, Anna Giuliani, Viviana Finato, Mariano Feriani, Armando Filippini, Loris Neri, Lucia Lisi
BACKGROUND: The original peritoneal equilibration test (PET) was used to classify peritoneal dialysis (PD) patients using a 2.27% glucose solution. It has since been suggested that a 3.86% glucose solution be used because this provides better information about ultrafiltration (UF) capacity and the sodium (Na) sieving of the peritoneal membrane. OBJECTIVE: The aim of this study was to determine reference values for a PET using a 3.86% glucose solution (PET-3.86%)...
July 11, 2017: Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
https://www.readbyqxmd.com/read/28685187/compatibility-of-fosfomycin-with-different-commercial-peritoneal-dialysis-solutions
#3
M Kussmann, A Baumann, S Hauer, P Pichler, M Zeitlinger, M Wiesholzer, H Burgmann, W Poeppl, G Reznicek
For treatment of peritoneal dialysis-related peritonitis, intraperitoneal administration of antibiotics remains the preferable route. For home-based therapy, patients are commonly supplied with peritoneal dialysis fluids already containing antimicrobial agents. The present study set out to investigate the compatibility of fosfomycin with different peritoneal dialysis fluids, namely, Extraneal(®), Nutrineal(®), Physioneal(®) 1.36% and Physioneal(®) 2.27%, under varying storage conditions. The peritoneal dialysis fluid bags including 4 g fosfomycin were stored over 14 days at refrigeration temperature (6°C) and room temperature (25°C) and over 24 h at body temperature (37°C)...
July 6, 2017: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/28676511/absence-of-post-transplantation-encapsulating-peritoneal-sclerosis-after-relatively-short-exposure-to-peritoneal-dialysis-prospective-analysis-using-repeated-abdominal-ct-scanning
#4
Alferso C Abrahams, Maaike K van Gelder, Jan Willem van der Veer, Pim A de Jong, Maarten S van Leeuwen, Walther H Boer
BACKGROUND: Encapsulating peritoneal sclerosis (EPS) is the most severe complication of peritoneal dialysis (PD). Several retrospective reports published between 2007 and 2009 have suggested an increasing incidence of EPS occurring after kidney transplantation. We conducted a prospective observational study to determine the incidence of post-transplantation EPS and identify possible risk factors. METHODS: Consecutive PD patients undergoing kidney transplantation between 2009 and 2013 were included...
July 2017: Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
https://www.readbyqxmd.com/read/28676508/the-potential-cardiovascular-benefits-of-low-glucose-degradation-product-biocompatible-peritoneal-dialysis-fluids-a-review-of-the-literature
#5
REVIEW
Charlotte E Grantham, Katherine L Hull, Matthew P M Graham-Brown, Daniel S March, James O Burton
Cardiovascular mortality in the end-stage renal disease (ESRD) population remains the leading cause of death. Targeting traditional cardiovascular risk factors has proven unsuccessful in this patient population, and therefore attention has turned to risk factors related to chronic kidney disease (CKD). The toxicity of high-glucose peritoneal dialysis (PD) solutions has been well documented. The breakdown of glucose into glucose degradation products (GDP) and advanced glycation end-products (AGE) has the ability to alter cell viability and cause premature apoptosis and is strongly correlated with interstitial fibrosis and microvascular sclerosis...
July 2017: Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
https://www.readbyqxmd.com/read/28674854/icodextrin-and-peritoneal-dialysis-advantages-and-new-applications
#6
REVIEW
Periklis Dousdampanis, Carlos Guido Musso, Konstantina Trigka
The impact of icodextrin (ico) on peritoneal dialysis (PD) extension and patient survival is well established. Predominantly, ico-based solutions were prescribed in high-transporter PD patients. Advantages of the ico-based solutions include increased biocompatibility, avoidance of glucotoxicity, enhanced ultrafiltration failure (UF), sodium removal rates, better metabolic and blood pressure control. Bimodal solutions and twice daily exchanges of ico-based solutions are two newly introduced strategies to avoid glucose exposure and/or enhance UF in PD patients with UF failure...
July 3, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28659813/human-peritoneal-mesothelial-cell-death-induced-by-high-glucose-hypertonic-solution-involves-ca-2-and-na-ions-and-oxidative-stress-with-the-participation-of-pkc-nox2-and-pi3k-akt-pathways
#7
Felipe Simon, Pablo Tapia, Ricardo Armisen, Cesar Echeverria, Sebastian Gatica, Alejandro Vallejos, Alejandro Pacheco, Maria E Sanhueza, Miriam Alvo, Erico Segovia, Rubén Torres
Chronic peritoneal dialysis (PD) therapy is equally efficient as hemodialysis while providing greater patient comfort and mobility. Therefore, PD is the treatment of choice for several types of renal patients. During PD, a high-glucose hyperosmotic (HGH) solution is administered into the peritoneal cavity to generate an osmotic gradient that promotes water and solutes transport from peritoneal blood to the dialysis solution. Unfortunately, PD has been associated with a loss of peritoneal viability and function through the generation of a severe inflammatory state that induces human peritoneal mesothelial cell (HPMC) death...
2017: Frontiers in Physiology
https://www.readbyqxmd.com/read/28624215/periostin-binding-dna-aptamer-treatment-ameliorates-peritoneal-dialysis-induced-peritoneal-fibrosis
#8
Bo Young Nam, Jung Tak Park, Young Eun Kwon, Jung Pyo Lee, Jong Ha Jung, Youndong Kim, Seonghun Kim, Jimin Park, Jae Eun Um, Meiyan Wu, Seung Hyeok Han, Tae-Hyun Yoo, Shin-Wook Kang
Peritoneal fibrosis is a major complication in peritoneal dialysis (PD) patients, which leads to dialysis discontinuation. Periostin, increased by transforming growth factor β1 (TGF-β1) stimulation, induces the expression of extracellular matrix (ECM) genes. Aberrant periostin expression has been demonstrated to be associated with PD-related peritoneal fibrosis. Therefore, the effect of periostin inhibition by an aptamer-based inhibitor on peritoneal fibrosis was evaluated. In vitro, TGF-β1 treatment upregulated periostin, fibronectin, α-smooth muscle actin (α-SMA), and Snail expression and reduced E-cadherin expression in human peritoneal mesothelial cells (HPMCs)...
June 16, 2017: Molecular Therapy. Nucleic Acids
https://www.readbyqxmd.com/read/28576435/-encapsulating-peritoneal-sclerosis
#9
Jean-Philippe Ryckelynck, Clémence Béchade, Nicolas Bouvier, Maxence Ficheux, Bruno Hurault de Ligny, Thierry Lobbedez
Encapsulating peritoneal sclerosis is a rare but devastating complication of long-term peritoneal dialysis with a high mortality rate. The incidence is between 0.5 and 2.5%, decreasing with time. PSE is defined as a clinical syndrome with signs of gastrointestinal obstruction, inflammation parameters, radiological and macroscopic changes. The duration of treatment and the cessation of peritoneal dialysis are the main risks. About 75% occured in patients on hemodialysis or after kidney transplantation. Morphological alterations are disappearance of mesothelial layer, submesothelial fibrosis, interstitial sclerosis and vasculopathy...
May 30, 2017: Néphrologie & Thérapeutique
https://www.readbyqxmd.com/read/28573488/peritoneal-dialysis-related-infections-recommendations-2016-update-what-is-new
#10
REVIEW
Vassilios Liakopoulos, Olga Nikitidou, Theofanis Kalathas, Stefanos Roumeliotis, Marios Salmas, Theodoros Eleftheriadis
In 2016, the International Society of Peritoneal Dialysis (ISPD) published guidelines that focus on the importance of both prevention and treatment of peritonitis. For once more, the need for annual reporting of peritonitis rates and recording of peritonitis and exit-site infections, isolated microorganism and antimicrobial susceptibilities as a central component of a quality improvement program is highlighted. Data on new antibiotic regimens, techniques for microorganism isolation and peritoneal dialysis solutions are included...
June 1, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28546366/characteristics-and-clinical-outcomes-of-end-stage-renal-disease-patients-on-peritoneal-dialysis-for-over-15-years-a-single-center-experience
#11
Youn Kyung Kee, Jung Tak Park, Chang-Yun Yoon, Hyoungnae Kim, Seohyun Park, Hae Ryong Yun, Su-Young Jung, Jong Hyun Jhee, Hyung Jung Oh, Seung Hyeok Han, Tae-Hyun Yoo, Shin-Wook Kang
♦Background: Maintaining peritoneal dialysis (PD) for a long time is problematic owing to a number of factors. This study aimed to clarify the characteristics and examine the clinical outcomes of patients who received PD as a long-term dialysis modality. ♦ Methods: All end-stage renal disease (ESRD) patients who initiated PD at Yonsei University Health System between 1987 and 2000 were screened. Patients who maintained PD for over 15 years were classified as the long-term PD group and those who were treated with PD for less than 5 years were included in the short-term PD group...
May 25, 2017: Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
https://www.readbyqxmd.com/read/28540200/targeting-cannabinoid-signaling-for-peritoneal-dialysis-induced-oxidative-stress-and-fibrosis
#12
REVIEW
Chih-Yu Yang, Yat-Pang Chau, Ann Chen, Oscar Kuang-Sheng Lee, Der-Cherng Tarng, An-Hang Yang
Long-term exposure to bioincompatible peritoneal dialysis (PD) solutions frequently results in peritoneal fibrosis and ultrafiltration failure, which limits the life-long use of and leads to the cessation of PD therapy. Therefore, it is important to elucidate the pathogenesis of peritoneal fibrosis in order to design therapeutic strategies to prevent its occurrence. Peritoneal fibrosis is associated with a chronic inflammatory status as well as an elevated oxidative stress (OS) status. Beyond uremia per se, OS also results from chronic exposure to high glucose load, glucose degradation products, advanced glycation end products, and hypertonic stress...
May 6, 2017: World Journal of Nephrology
https://www.readbyqxmd.com/read/28540060/microparticle-formation-in-peritoneal-dialysis-a-proof-of-concept-study
#13
Shareef Akbari, Rima Abou-Arkoub, Suzy Sun, Swapnil Hiremath, Arkadiy Reunov, Brendan B McCormick, Marcel Ruzicka, Dylan Burger
BACKGROUND: Injury to the mesothelial layer of the peritoneal membrane during peritoneal dialysis (PD) is implicated in loss of ultrafiltration capacity, but there are no validated biomarkers for mesothelial cell injury. Microparticles (MPs) are 0.1 to 1.0 µm membrane vesicles shed from the cell surface following injury and are sensitive markers of tissue damage. Formation of MPs in the peritoneal cavity during PD has not been reported to date. METHODS: We designed a single-center, proof of concept study to assess whether peritoneal solution exposure induces formation of mesothelial MPs suggestive of PD membrane injury...
2017: Canadian Journal of Kidney Health and Disease
https://www.readbyqxmd.com/read/28525669/relationship-between-bioimpedance-determined-body-composition-and-peritoneal-transport-in-peritoneal-dialysis
#14
Bernardo M da Costa, Gloria Del Peso, Maria Auxiliadora Bajo, Gilda Carreño, Marta Ferreira, Carina Ferreira, Rafael Selgas
PURPOSE: In peritoneal dialysis (PD) patients, body fluid homeostasis is dependent on peritoneal elimination of water and solutes. Patients with less favorable peritoneal transport parameters should be more overhydrated. Despite this, the association between faster transport and overhydration (OH) is weak, and the factors that influence hydration status are still poorly characterized. Modified peritoneal equilibration tests (PET) offer us new parameters that might correlate better with hydration status, like free water transport (FWT)...
May 18, 2017: International Journal of Artificial Organs
https://www.readbyqxmd.com/read/28504180/the-glycogen-of-galdieria-sulphuraria-as-alternative-to-starch-for-the-production-of-slowly-digestible-and-resistant-glucose-polymers
#15
Marta Martinez-Garcia, Akrivi Kormpa, Marc J E C van der Maarel
Highly branched glucose polymers produced from starch are applied in various products, such as peritoneal dialysis solutions and sports drinks. Due to its insoluble, granular nature, the use of native starch as substrate requires an energy consuming pre-treatment to achieve solubilization at the expense of process costs. Glycogen, like starch, is also a natural glucose polymer that shows more favorable features, since it is readily soluble in cold water and more accessible by enzymes. The extremophilic red microalga Galdieria sulphuraria accumulates large amounts of a small, highly branched glycogen that could represent a good alternative to starch as substrate for the production of highly branched glucose polymers...
August 1, 2017: Carbohydrate Polymers
https://www.readbyqxmd.com/read/28486991/exploring-the-utility-and-scalability-of-a-telehomecare-intervention-for-patients-with-chronic-kidney-disease-undergoing-peritoneal-dialysis-a-study-protocol
#16
Lianne Jeffs, Arsh Kumar Jain, Rachel HiuTung Man, Nike Onabajo, Laura Desveaux, James Shaw, Jennifer Hensel, Payal Agarwal, Marianne Saragosa, Trevor Jamieson, Ivy Wong, Maria Maione, R Sacha Bhatia
BACKGROUND: Chronic Kidney Disease (CKD) is a pressing global health concern that is placing increased strain on health care resources. CKD patients regularly receive peritoneal dialysis as a common CKD treatment. An emerging technological solution is telehomecare as way to support patients receiving PD in their homes. This study protocol outlines a mixed methods evaluation exploring a telehomecare developed to enhance CKD patients' outcomes and experiences. The study aims to assess the usability, acceptability and scalability of this virtual care application...
May 10, 2017: BMC Nephrology
https://www.readbyqxmd.com/read/28408714/association-between-peritoneal-glucose-exposure-and-peritonitis-in-peritoneal-dialysis-patients-the-balanz-trial
#17
Melissa Nataatmadja, Yeoungjee Cho, Elaine M Pascoe, Darsy Darssan, Carmel M Hawley, David W Johnson
BACKGROUND: Glucose is the primary osmotic medium used in most peritoneal dialysis (PD) solutions, and exposure to glucose has been shown to exert detrimental effects both locally, at the peritoneal membrane, and systemically. Moreover, high dialysate glucose exposure may predispose patients to an increased risk of peritonitis, perhaps as a result of impaired host defences, vascular disease, and damage to the peritoneal membrane. METHODS: In this post-hoc analysis of a multicenter, multinational, open-label randomized controlled trial of neutral pH, low-glucose degradation product (GDP) versus conventional PD solutions (balANZ trial), the relationship between peritonitis rates of low (< 123...
July 2017: Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
https://www.readbyqxmd.com/read/28393968/-encapsulating-peritoneal-sclerosis
#18
Rubén Torres, Paula Ebner, María Eugenia Sanhueza, Miriam Alvo, Erico Segovia, Paula Segura
BACKGROUND: Encapsulating peritoneal sclerosis (EPS) is a complication of peritoneal dialysis (PD) with a low prevalence but high mortality. It is characterized by peritoneal inflammation and fibrosis with subsequent development of intestinal encapsulation. It is associated with a long lapse on PD, frequent episodes of peritonitis, high glucose solution use, and high peritoneal transport status. AIM: To report the clinical features of patients on PD, who developed EPS...
January 2017: Revista Médica de Chile
https://www.readbyqxmd.com/read/28362076/a-systematic-review-of-preclinical-studies-on-therapeutic-potential-of-stem-cells-or-stem-cells-products-in-peritoneal-fibrosis
#19
Sudabeh Alatab, Iraj Najafi, Rasha Atlasi, Gholamreza Pourmand, Ozra Tabatabaei-Malazy, Naser Ahmadbeigi
INTRODUCTION: Peritoneal fibrosis remains a serious complication of long-term peritoneal dialysis. Stem cell therapy is an innovative field of scientific investigation with potential for clinical application. Here, we systematically reviewed the studies to determine whether stem cell based therapy could improve the peritoneal fibrosis in experimental models of peritoneal fibrosis. EVIDENCE ACQUISITION: Our systematic search of Pubmed, Scopus, Web of Science, and Cochrane Library yield 5219 article...
March 31, 2017: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
https://www.readbyqxmd.com/read/28264139/residual-kidney-function-implications-in-the-era-of-personalized-medicine
#20
Tariq Shafi, Surekha Mullangi, Stephanie M Toth-Manikowski, Seungyoung Hwang, Wieneke M Michels
The association of residual kidney function (RKF) with improved outcomes in peritoneal dialysis and hemodialysis patients is now widely recognized. RKF provides substantial volume and solute clearance even after dialysis initiation. In particular, RKF provides clearance of nonurea solutes, many of which are potential uremic toxins and not effectively removed by conventional hemodialysis. The presence of RKF provides a distinct advantage to incident dialysis patients and is an opportunity for nephrologists to individualize dialysis treatments tailored to their patients' unique solute, volume, and quality of life needs...
May 2017: Seminars in Dialysis
keyword
keyword
20986
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"